术后疼痛难题，以岭给了新解法

Core Viewpoint - The article discusses the launch of a new non-opioid analgesic drug, Benanilofen injection, developed by Yiling Pharmaceutical, aimed at addressing postoperative pain management, which affects nearly 70% of surgical patients in China [3][9]. Group 1: Market Context and Demand - In 2024, China's healthcare institutions are expected to have 312 million hospitalized patients, with 104 million surgical procedures, reflecting an 8% increase from 2023 [3]. - A significant portion of surgical patients experience moderate to severe postoperative pain, highlighting the need for effective pain management solutions [3][8]. Group 2: Product Overview - Benanilofen is designed for postoperative pain relief following abdominal and thoracoscopic surgeries, marking a significant advancement in the field of analgesics [3][9]. - The drug aims to optimize the postoperative pain experience by ensuring stable analgesic effects while enhancing safety [9]. Group 3: Company Strategy and R&D Investment - Yiling Pharmaceutical has shifted its focus from traditional Chinese medicine to include chemical drug development, with Benanilofen being its first approved chemical patent drug [12][14]. - The company has significantly increased its R&D investment from 240 million yuan in 2016 to over 900 million yuan in 2024, representing 13.94% of its revenue [12][13]. - Yiling's R&D pipeline includes nine new traditional Chinese medicines and four innovative chemical drugs, indicating a robust commitment to drug development [13][14]. Group 4: Competitive Landscape - The launch of Benanilofen is expected to disrupt the postoperative pain management market, traditionally dominated by imported drugs, by providing a safer and more effective local alternative [17][18]. - Clinical trial results place Benanilofen among the top non-steroidal anti-inflammatory drugs, showcasing its competitive edge in the market [17]. Group 5: Industry Implications - The success of Yiling's chemical drug development serves as a reminder to local pharmaceutical companies that true innovation lies in addressing unmet clinical needs rather than merely following market trends [18].